ReGen CEO criticizes decision to rescind knee implant's clearance

10/19/2010 | Wall Street Journal, The

The FDA's plan to nullify the 510(k) clearance of ReGen Biologics' Menaflex knee implant was "totally unbelievable" and is being driven by a "political agenda," according to ReGen CEO Gerald Bisbee. Dr. Jeffrey Shuren, head of the FDA's device unit, countered the company's statement, saying the agency thoroughly reviewed the process for clearing the device and has the power to revoke the approval.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations